Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Florian Huemer 1, * , Gabriel Rinnerthaler 1, * , Theresa Westphal 1 , Hubert Hackl 4 , Georg Hutarew 5 , Simon Peter Gampenrieder 1 , Lukas Weiss 1 and Richard Greil 1, 2, 3 1 IIIrd Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria 2 Salzburg Cancer Research Institute (SCRI), Salzburg, Austria 3 Cancer Cluster Salzburg (CCS), Salzburg, Austria 4 Division of Bioinformatics, Biocenter, Medical University of Innsbruck, Innsbruck, Austria 5 Institute of Pathology, Paracelsus Medical University Salzburg, Salzburg, Austria * These authors have contributed equally to this work Correspondence to: Richard Greil, email: r.greil@salk.at Keywords: immune-checkpoint blockade; antibiotics; non-squamous non-small cell lung cancer; progression-free survival; overall survival Received: October 19, 2017 Accepted: March 05, 2018 Published: March 27, 2018 ABSTRACT Introduction: Despite durable responses from immune-checkpoint blockade (ICB) in a subset of patients with advanced non-small cell lung cancer (NSCLC), the majority of patients do not derive benefit from this treatment. In this analysis we evaluated the impact of concomitant administration of antibiotics during initiation of ICB on clinical outcome. Methods: Advanced non-squamous NSCLC patients receiving ICB as second- or later line between 2015 and 2017 at our tertiary cancer center in Salzburg (Austria) were included. Concomitant use of antibiotics was defined as administration of antibiotics within a time frame of one month before or one month after initiation of ICB (AB + -group). Results: Of the 30 patients included, 11 (36.7%) received antibiotics one month before or one month after start of ICB (AB + -group). Median PFS on ICB was in favor of the AB - -group (AB - : 3.1 months [95%CI: 3.0-16.3]; AB + : 2.9 months, [95%CI: 1.9-NA]; HR=0.46 [95%CI: 0.12-0.90], p=0.031). Furthermore, median OS was significantly longer in the AB - -group (AB - : 15.1 months [95%CI: 11.1-NA]; AB + : 7.5 months [95%CI: 6.3-NA]; HR=0.31 [95%CI: 0.02-0.78], p=0.026). In a multivariate analysis, the antibiotic treatment status was identified as the only parameter statistically significantly associated with PFS (p=0.028) and OS (p=0.026). Conclusions: Stratification of patients according to the antibiotic treatment status is warranted in future trials investigating ICB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 2×
“Animal studies suggest that the relative abundance of certain bacterial species such as Bifidobacterium is crucial for dendritic cell maturation, enhanced cytotoxic T-lymphocyte (CTL) priming, accumulation of CTL in the tumor microenvironment and finally for the efficacy of ICB [8].”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 1×
“Preclinical studies assume an influence of the composition of the gut microbiota on the benefit from ICB by improving dendritic cell function and T-cell activation [7, 8].”
BackgroundCheckpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis
Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839 · cited 1×
“Non-squamous NSCLC patients harboring an activating mutation of the epidermal growth factor receptor (EGFR) gene might derive less benefit from ICB as previously reported [4, 11].”
Background
Cited by
Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz206 · Cited by 246
Elkrief, A., El Raichani, L., Richard, C., Messaoudene, M., Belkaid, W., Malo, J., Belanger, K., Miller, W., Jamal, R., Letarte, N., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1568812 · Cited by 208
“026) with multivariate analysis confirming that ATB use was the only parameter of statistical significance associated with worse PFS and OS.(15)”
MethodInfluentialTinsley, N., Zhou, C., Tan, G., Rack, S., Lorigan, P., Blackhall, F., Krebs, M., Carter, L., Thistlethwaite, F., Graham, D., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0160 · Cited by 201
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E., Gedye, C., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 187
“lung cancer (1192, 1193), and metastatic melanoma (1194), and in cancers more”
BackgroundZhao, S., Gao, G., Li, W., Li, X., Zhao, C., Jiang, T., Jia, Y., He, Y., Li, A., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.01.017 · Cited by 164
Metadata
- Authors
- Huemer, F., Rinnerthaler, G., Westphal, T., Hackl, H., Hutarew, G., Gampenrieder, S. P., Weiss, L., & Greil, R.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2018-03-27
- Volume
- 9
- Issue
- 23
- Pages
- 16512-16520
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2795291772
- Cited by
- 87
- References
- 5
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. https://app.cochat.ai/papers/10.18632/oncotarget.24751
- The paper
- Huemer, F., Rinnerthaler, G., Westphal, T., Hackl, H., Hutarew, G., Gampenrieder, S. P., Weiss, L., & Greil, R. (2018). Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. Oncotarget. https://doi.org/10.18632/oncotarget.24751
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.